Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Korean study finds no overall childhood cancer link with maternal diabetes

4

Aug 2026

Korean study finds no overall childhood cancer link with maternal diabetes

Researchers followed 549,851 Korean children and found no statistically significant association between maternal diabetes and overall childhood cancer. The analysis linked maternal diabetes to an 81% higher relative risk of urinary tract cancer, but the absolute difference was only 37 additional cases per 100,000 offspring.

High childhood body mass index linked to adult childlessness

4

Aug 2026

High childhood body mass index linked to adult childlessness

A study of almost 61,000 women in Denmark, published in the journal JAMA Network Open, finds that women who had an overweight or obesity body mass index (BMI) trajectory during childhood were less likely to have children than women with a normal (average) BMI trajectory, and this effect on childlessness was already apparent in their mid-20s.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.